dc.contributor.author | Tarhini, AA | |
dc.contributor.author | Toor, K | |
dc.contributor.author | Chan, K | |
dc.contributor.author | McDermott, DF | |
dc.contributor.author | Mohr, P | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Hodi, FS | |
dc.contributor.author | Lee, C-H | |
dc.contributor.author | Rizzo, JI | |
dc.contributor.author | Johnson, H | |
dc.contributor.author | Moshyk, A | |
dc.contributor.author | Rao, S | |
dc.contributor.author | Kotapati, S | |
dc.contributor.author | Atkins, MB | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-08-19T12:02:43Z | |
dc.date.available | 2022-08-19T12:02:43Z | |
dc.date.issued | 2021-02-06 | |
dc.identifier | ARTN 100050 | |
dc.identifier | S2059-7029(21)00004-1 | |
dc.identifier.citation | ESMO Open, 2021, 6 (2), pp. 100050 - | en_US |
dc.identifier.issn | 2059-7029 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5283 | |
dc.identifier.eissn | 2059-7029 | |
dc.identifier.eissn | 2059-7029 | |
dc.description.abstract | BACKGROUND: Approved first-line treatments for patients with BRAF V600-mutant advanced melanoma include nivolumab (a programmed cell death protein 1 inhibitor) plus ipilimumab (a cytotoxic T lymphocyte antigen-4 inhibitor; NIVO+IPI) and the BRAF/MEK inhibitors dabrafenib plus trametinib (DAB+TRAM), encorafenib plus binimetinib (ENCO+BINI), and vemurafenib plus cobimetinib (VEM+COBI). Results from prospective randomized clinical trials (RCTs) comparing these treatments have not yet been reported. This analysis evaluated the relative efficacy and safety of NIVO+IPI versus DAB+TRAM, ENCO+BINI, and VEM+COBI in patients with BRAF-mutant advanced melanoma using a matching-adjusted indirect comparison (MAIC). PATIENTS AND METHODS: A systematic literature review identified RCTs for DAB+TRAM, ENCO+BINI, and VEM+COBI in patients with BRAF-mutant advanced melanoma. Individual patient-level data for NIVO+IPI were derived from the phase III CheckMate 067 trial (BRAF-mutant cohort) and restricted to match the inclusion/exclusion criteria of the comparator trials. Treatment effects for overall survival (OS) and progression-free survival (PFS) were estimated using Cox proportional hazards and time-varying hazard ratio (HR) models. Safety outcomes (grade 3 or 4 treatment-related adverse events) with NIVO+IPI and the comparators were compared. RESULTS: In the Cox proportional hazards analysis, NIVO+IPI showed improved OS compared with DAB+TRAM (HR = 0.53; 95% confidence interval [CI], 0.39-0.73), ENCO+BINI (HR = 0.60; CI, 0.42-0.85), and VEM+COBI (HR = 0.50; CI, 0.36-0.70) for the overall study period. In the time-varying analysis, NIVO+IPI was associated with significant improvements in OS and PFS compared with the BRAF/MEK inhibitors 12 months after treatment initiation. There were no significant differences between NIVO+IPI and BRAF/MEK inhibitor treatment from 0 to 12 months. Safety outcomes favored DAB+TRAM over NIVO+IPI, whereas NIVO+IPI was comparable to VEM+COBI. CONCLUSION: Results of this MAIC demonstrated durable OS and PFS benefits for patients with BRAF-mutant advanced melanoma treated with NIVO+IPI compared with BRAF/MEK inhibitors, with the greatest benefits noted after 12 months. | |
dc.format | Print-Electronic | |
dc.format.extent | 100050 - | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER | en_US |
dc.relation.ispartof | ESMO Open | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | BRAF/MEK inhibitors | |
dc.subject | advanced melanoma | |
dc.subject | ipilimumab | |
dc.subject | matching-adjusted indirect comparison | |
dc.subject | nivolumab | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Humans | |
dc.subject | Ipilimumab | |
dc.subject | Melanoma | |
dc.subject | Mitogen-Activated Protein Kinase Kinases | |
dc.subject | Nivolumab | |
dc.subject | Proto-Oncogene Proteins B-raf | |
dc.title | A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-01-05 | |
dc.date.updated | 2022-08-19T12:01:57Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1016/j.esmoop.2021.100050 | en_US |
rioxxterms.licenseref.startdate | 2021-02-06 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33556898 | |
pubs.issue | 2 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 6 | |
dc.contributor.icrauthor | Larkin, James | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Prof James Larkin) on 2022-08-19. Deposit type is initial. No. of files: 1. Files: A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treat.pdf | |